FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 327 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Preparación para el fin de la emergencia de salud pública (PHE)... April 3, 2023 Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia June 22, 2018 Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies March 17, 2023 Mom Diagnosed With Stage III Breast Cancer While Nursing Her 9-Month-Old... May 20, 2020 Load more HOT NEWS Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling... Radionuclide Therapy Could Be A Viable Treatment For Early-Stage Breast Cancer,... Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC... Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in...
